Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comparison of Safety and Clinical Benefit of Injections Subcutaneously Talazoparib Versus Oral Talazoparib in Patients With Advanced Solid Tumors ( Phase I )

NCT03426254 is registered in ClinicalTrials.gov with Center Trials & Treatment as lead sponsor.

NCT NCT03426254
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03426254 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Comparison of Safety and Clinical Benefit of Injections Subcutaneously Talazoparib Versus Oral Talazoparib in Patients With Advanced Solid Tumors ( Phase I )
Lead sponsor
Center Trials & Treatment
Phase
Phase 1
Overall status
Withdrawn
Start date
November 10, 2022
Completion date
January 10, 2024
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced or recurrent solid tumors, breast neoplasm